Overall, only a small subset of ferroptosis-related biomarkers (e.g., SLC7A11, GPX4, EBV DNA kinetics) have been correlated with clinical outcomes in NPC, and none of the therapeutic combinations described have progressed into clinical testing, reflecting a substantial gap between mechanistic insights and clinical translation. This evidence concerns the gene GPX4 and nasopharyngeal carcinoma.